Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APA Immuno-Liposome
- Development stage
- Preclinical
- Lead developer
- APA Advanced Technologies
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
APA Immuno-Liposome (AIL) is a preclinical-stage fusogenic immunoliposome platform being developed by APA Advanced Technologies for the treatment of triple-negative breast cancer (TNBC). The platform is designed to selectively bind to cancer cells and fuse with the tumor-cell membrane, subsequently displaying a humanized anti-CD3 antibody on the cell surface. This display of anti-CD3 recruits and activates human T cells directly at the tumor site, triggering a localized immune response against the cancer cells. Preclinical in vitro studies are focused on characterizing the components of the AIL immunoliposome and evaluating its activity using T cells from healthy blood donors and TNBC patients.
- Other names
- AIL immunoliposomeAIL immunoliposome platform
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on APA Immuno-Liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APA Immuno-Liposome.